NEKTAR THERAPEUTICS NKTR
- NKTR-255 — Large B-Cell Lymphoma Phase 2
- NKTR-255 — Urothelial Carcinoma Phase 2
- NKTR-255 — Non-Small Cell Lung Cancer Phase 2
IL-15 (3 companies · 6 programs)
Companies with an active program directed at IL-15.
ImmunityBio, Inc. IBRX
- ANKTIVA — Non-Muscle Invasive Bladder Cancer NDA Submitted
- ANKTIVA — Non-Small Cell Lung Cancer Phase 2
Forte Biosciences, Inc. FBRX
- FB102 — Vitiligo Phase 1